Awareness and clinical management of metabolic dysfunction-associated steatotic liver disease among physicians in Milan: a cross-sectional survey

Metabolic dysfunction-associated steatotic liver disease (MASLD) is defined within the new steatotic liver disease nomenclature and requires assessment of cardiometabolic risk factors, with increasing emphasis on appropriate non-invasive assessment of liver fibrosis [1]. The transition from the previous NAFLD terminology to MASLD within the broader steatotic liver disease (SLD) umbrella, the validation of clinical referral pathways and the approval of the new pharmaceutical approaches to treat MASLD associated with liver fibrosis represent major advances and important changes in clinical practice and may require specific educational efforts across different medical settings.